Copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2007
The Cutting Edge article “Successful Treatment of Severe Atopic Dermatitis in a Child and an Adult With the T-Cell Modulator Efalizumab”1 in the May 2006 issue of the ARCHIVES discusses another medication for this disease with both short- and long-term potential for toxic effects added to the panoply of similar medications, including azathioprine, mycophenolate, cyclosporine, and other immunomodulators. As yet unknown adverse effects of efalizumab might preclude its long-term use. I suggest another approach to the “problem” of atopy before instituting treatments with new medications.
Rapaport M. Rebound Vasodilation From Long-term Topical Corticosteroid Use. Arch Dermatol. 2007;143(2):264–276. doi:10.1001/archderm.143.2.268-b
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: